Navigation Links
USPTO issues patent for "Preservation by Vaporization" technology, allowing manufacture of thermostable vaccines and other fragile biopharmaceuticals
Date:11/16/2016

SAN DIEGO, Nov. 16, 2016 /PRNewswire/ -- USPTO has issued a patent for a novel manufacturing process, "Preservation by Vaporization" (PBV),  invented by Dr. Victor Bronshtein, Founder, President and Chief Scientific Officer of Universal Stabilization Technologies, Inc. (UST).  This invention eliminates the need for the cold chain during storage, distribution and delivery of labile biotherapeutics. Additionally, it allows the product to be micronized into powders suitable for administration by respiratory, transdermal, oral, intravaginal, or other mucosal delivery routes, eliminating the need for both reconstitution and needle injection.

PBV can be used to preserve live attenuated vaccines (LAV) and other labile biologics, endowing them with the ambient temperature (AT) stability that is typically only possible with pharmaceuticals. Despite years of optimization, conventional freeze drying and spray drying methods have been unable to successfully thermostabilize LAVs and many other fragile biopharmaceuticals.  For this reason, most fragile biopharmaceuticals, probiotic bacteria, blood-derived products, and enzyme based diagnostics, preserved using conventional drying methods, require a well-controlled cold chain to retain potency and activity. Lack or breakdown of refrigeration for vaccines results in billions of dollars' worth of product loss during shipping and storage, and severely limits distribution to developing nations that lack infrastructure for electricity and refrigeration. Cold chain requirements are estimated to account for over 80% the cost of vaccine implementation, an expense of $200-$300 million annually for vaccination programs. Thermostable biotherapeutics, manufactured via the alternative PBV method, can alleviate these major economic and logistical burdens, which present challenges especially to developing nations.

The novel PBV process is the cornerstone of UST's VitriLife® platform for formulation and production of thermostable LAVs and biopharmaceuticals immobilized in foamed carbohydrate glasses for long-term AT stability.  PBV-enabled thermostability and alternative delivery methods are important differentiating factors for production of biobetter vaccines and other biologics.  Thermostable biobetters have the potential to take a large market share of the multibillion dollar biosimilars market. 

About:
UST is a privately held San Diego-based biopharmaceutical R&D company focused on the formulation of long-term ambient temperature stable biopharmaceuticals.  UST offers VitriLife® research and development services for its customers as well as formulation of oral, respiratory, transdermal, sublingual, and other delivery devices for AT stable vaccines and other biopharmaceuticals.  

Contact:   

Universal Stabilization Technologies, Inc. 4050 Sorrento Valley Blvd. Ste. L, San Diego, CA 92121
Tel. 858-625-2896, alexs@vitrilife.com, Website: www.vitrilife.com     

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uspto-issues-patent-for-preservation-by-vaporization-technology-allowing-manufacture-of-thermostable-vaccines-and-other-fragile-biopharmaceuticals-300363547.html


'/>"/>
SOURCE Universal Stabilization Technologies, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. American Process, Inc. Announces Sulfite Nanocellulose Patent Allowed by USPTO
2. American Process, Inc. Announces Additional Nanocellulose Patents Granted by USPTO
3. ProteoThera, Inc. Receives USPTO Grant of Key Patent Supporting Matrix-Binding Technology Platform
4. Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
5. KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511
6. Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology
7. Noninvasive Imaging Technique Protects Healthy Tissues During Freezing of Cancer Lesions
8. ComplianceOnline Announces Seminar on Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions
9. Enabling Technologies Consortium (ETC) Issues Request for Information (RFI) Regarding Development of Medium Throughput Personal Reactor Platform
10. Edison Issues ADR Update on Midatech
11. Dr. Paul Janssen Award for Biomedical Research Issues 2016 Call for Nominations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2018)... ... November 29, 2018 , ... RAGS, today announced the ... Kickstart Seed Fund, with participation from existing investor and board member Jeremy Andrus, CEO ... of Cotopaxi. The additional funding will enable the company to accelerate its growth and ...
(Date:11/26/2018)... , ... November 26, 2018 , ... ... backed by Siemens Healthineers and Omphalos Venture Partners (Virtual Radiologic founders) among other ... Meeting from Nov. 25-29 at McCormick Place in Chicago. The company is proud ...
(Date:11/20/2018)... , ... November 20, 2018 , ... Each year Forbes ... Under 30 list which highlights outstanding performance by individuals under 30 years of age. ... range of fields from Sports and Entertainment to Venture Capital and Science. , ...
(Date:11/13/2018)... Calif. (PRWEB) , ... November 13, 2018 , ... Renowned ... to patients on the island of Kauai. Dr. Leadbeater, of Kahala Pet ... services since 2009. Recently, he began traveling to the island of Kauai on ...
Breaking Biology Technology:
(Date:12/13/2018)... (PRWEB) , ... December 12, 2018 , ... Illumina, Kaiser ... kitchen this year. The San Diego-based team-building and cooking events company has hosted ... building and corporate cooking challenges. , Each group who visits receives a ...
(Date:12/10/2018)... DIEGO, Calif. (PRWEB) , ... December 10, 2018 , ... ... biotherapeutics research, announces a headquarters relocation to 9640 Towne Centre Drive, Suite 100, effectively ... has seen exponential growth, both domestically and internationally, for the sales of our drug ...
(Date:12/5/2018)... ... December 05, 2018 , ... Surgical Theater brings familial patient ... December 6-9, 2018 at booth #312. AANS/CNS provides Pediatric Neurosurgeons an opportunity to ... continuum – from the consultation, to surgical planning, and into the operating room. ...
Breaking Biology News(10 mins):